


Pham Tran Viet Chuong MD MSc


Nguyen Hoang Dinh MD Phd A.Prof

UMC Heart Center, HCM City

Atrial fibrillation (AF)

- Characterized by an irregular and often fast heartbeat
- Uncoordinated contraction of 2 atria











- Most common arrythmia encountered (3% of the population).
- Higher incidence among patients presenting for MV surgery (30–50%).





Pathophysiology

- Pathophysiological mechanisms: UNCLEAR
- Triggers: a single rapidly firing focus in the atria
 (most frequently: pulmonary veins, muscular sleeves of the superior vena cava, coronary sinus or ligament of Marshall)
- Abnormalities of the atrial tissue substrate:
 fibrosis (excitation wavelets can and perpetuate
 the arrhythmia)




Sánchez-Quintana D, López-Mínguez JR, Pizarro G, et al. **Triggers and anatomical substrates in the genesis and perpetuation of atrial fibrillation**. Curr Cardiol Rev 2012;8:310-26.

Surgical ablation

MAZE concept:

- Lines of conduction block that preclude
 macro re-entry in either atrium while leaving
 both atria capable of activation by a sinus
 generated impulse.
- The maze has one entrance site, one exit site and one true route between the entrance and exit.



Cox JL, Churyla A, Malaisrie SC, Kruse J, et al. When is a MAZE procedure a MAZE procedure? The Canadian Journal of Cardiology. 2018;34(11):1482-1491



Surgical ablation


- MAZE IV:
- Using a combination of bipolar radiofrequency clamps and linear cryoprobes.
- Safe and effective -> Now the gold standard.
- Benefit: high SR restoration rate, improve symptom, Qol, stroke rate, survival rate.
- Cost: augmented PM implantation rate.





Minimally Invasive AF surgery

- Well established and accepted.
- Based on MAZE IV concept.
- Equivalent efficacy w. sternotomy approach.
- Event in long standing AF group.
- There was no 30-day mortality. Freedom from ATAs was 94%, 89%, and 77% at 1, 5, and 10 years, respectively.



MacGregor RM, Bakir NH, Pedamallu H, Sinn LA, Maniar HS, Melby SJ, Damiano RJ Jr. Late results after stand-alone surgical ablation for atrial fibrillation. J Thorac Cardiovasc Surg. 2022 Nov;164(5):1515-1528.e8. doi: 10.1016/j.jtcvs.2021.03.109. Epub 2021 Apr 17. PMID: 34045056; PMCID: PMC9536146.



Indication of AF surgery

2016 guidelines of the ESC, in collaboration with EACTS in the management of AF:

- MAZE surgery should be considered in **refractory symptomatic AF** or **post ablation AF** to reduce symptoms (Class IIa).
- MAZE surgery should be considered in symptomatic patients with AF
 (class IIa) and may be considered in asymptomatic patients in AF (Class IIb) in concomitant setting.




- 86 patients was retrospectively investigated (2017 2022).
- Concomitant MAZE IV in MI mitral or mitral and tricuspid surgery.
- Monopolar RF energy.
- LAA closure.
- Amiodarone: 3 months post op.
- AF recurrence is detected by Holter ECG.










- Working port at 4th ICS.
- VATs or Total endoscopic 3D surgery.









- Endocardial & epicardial ablation.
- 1 mm/s, 30W.





| Characteristic | N = 86 |
|-----------------------|----------------|
| Age | 58 (34;73) |
| Female | 72.1 (62) |
| BMI | 21.9 ± 3.6 |
| EF | 56.4 ± 6.6 |
| LA | 52 ± 13 mm |
| Long standing AF | 67 (77.9) |
| Percutaneous ablation | 0 (0) |



| Characteristic | N = 86 |
|---------------------------|---------------|
| НВР | 24 (27.9) |
| Diabetes | 11 (12.8) |
| Peripheral artery disease | 5 (5.8) |
| Stroke | 21 (24.4) |
| PAPs | 40 (30;49) |
| EuroSCORE II | 3.9 ± 1.5 |



| Characteristic | N = 86 |
|--------------------------|--------------|
| Mitral valve replacement | 73 (84.9) |
| Mitral valve repair | 13 (15.1) |
| Tricuspid valve repair | 34 (39.5) |
| LAAA closure | 86 (100) |
| Cross clamp time | 108.5 ± 20.8 |
| CPB time | 162.7 ± 34.3 |
| MAZE time | 13 ± 2 |



| Characteristic | N = 86 |
|---------------------------|------------|
| Conversion rate | 0 (0) |
| Re-exploration rate | 3 (3.5) |
| Neurological complication | 3 (3.5) |
| Intubation time | 19 (13;28) |
| Early mortality | 2 (2.4) |
| 30-day mortality | 0 (0) |

UMC Experience

• Mean follow up time: 18 months

• Successful rate: 77%

PM implantation rate: 10.4%.

• Stroke rate: 0%.

Mortality: 0%



TAKE HOME MESSAGE

- AF is fast becoming one of the world's most significant health issues that places a critical burden on healthcare systems.
- Maze procedure is safe and efficacy.
- The use of mini-invasive techniques for AF treatment has become widely accepted.
- Atrial Fibrillation Heart Team in management of AF.

